LC–MS Profiling of N-Glycans Derived from Human Serum Samples for Biomarker Discovery in Hepatocellular Carcinoma

Defining clinically relevant biomarkers for early stage hepatocellular carcinoma (HCC) in a high-risk population of cirrhotic patients has potentially far-reaching implications for disease management and patient health. Changes in glycan levels have been associated with the onset of numerous diseases including cancer. In the present study, we used liquid chromatography coupled with electrospray ionization mass spectrometry (LC–ESI-MS) to analyze N-glycans in sera from 183 participants recruited in Egypt and the U.S. and identified candidate biomarkers that distinguish HCC cases from cirrhotic controls. N-Glycans were released from serum proteins and permethylated prior to the LC–ESI-MS analysis. Through two complementary LC–ESI-MS quantitation approaches, global profiling and targeted quantitation, we identified 11 N-glycans with statistically significant differences between HCC cases and cirrhotic controls. These glycans can further be categorized into four structurally related clusters, matching closely with the implications of important glycosyltransferases in cancer progression and metastasis. The results of this study illustrate the power of the integrative approach combining complementary LC–ESI-MS based quantitation approaches to investigate changes in N-glycan levels between HCC cases and patients with liver cirrhosis.

[1]  Mary Ann Comunale,et al.  Increased Levels of Tetra-antennary N-Linked Glycan but Not Core Fucosylation Are Associated with Hepatocellular Carcinoma Tissue , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[2]  S. Nishimura,et al.  Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis , 2013, Hepatology.

[3]  Y. Mechref,et al.  Microscale nonreductive release of O-linked glycans for subsequent analysis through MALDI mass spectrometry and capillary electrophoresis. , 2001, Analytical chemistry.

[4]  Yehia Mechref,et al.  High-throughput solid-phase permethylation of glycans prior to mass spectrometry. , 2008, Rapid communications in mass spectrometry : RCM.

[5]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[6]  Yehia Mechref,et al.  Analysis of MALDI-TOF mass spectrometry data for detection of glycan biomarkers. , 2008, Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing.

[7]  Ajit Varki,et al.  alpha 2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo. , 2008, Cancer research.

[8]  C. Van Steenkiste,et al.  Alteration of protein glycosylation in liver diseases. , 2009, Journal of hepatology.

[9]  M. Bernardi,et al.  Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. , 2001, Journal of hepatology.

[10]  M. Monsigny,et al.  Increased alpha2,6 sialylation of N-glycans in a transgenic mouse model of hepatocellular carcinoma. , 1997, Cancer research.

[11]  R. Contreras,et al.  N‐glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus , 2007, Hepatology.

[12]  Joseph Zaia,et al.  Mass spectrometry and the emerging field of glycomics. , 2008, Chemistry & biology.

[13]  Yehia Mechref,et al.  Identifying cancer biomarkers by mass spectrometry‐based glycomics , 2012, Electrophoresis.

[14]  Navdeep Jaitly,et al.  Decon2LS: An open-source software package for automated processing and visualization of high resolution mass spectrometry data , 2009, BMC Bioinformatics.

[15]  R. Seruca,et al.  The role of N-acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E-cadherin. , 2009, Human molecular genetics.

[16]  M. Monsigny,et al.  Increased α2,6 Sialylation of N-Glycans in a Transgenic Mouse Model of Hepatocellular Carcinoma , 1997 .

[17]  J. Esko,et al.  The sweet and sour of cancer: glycans as novel therapeutic targets , 2005, Nature Reviews Cancer.

[18]  Yehia Mechref,et al.  Solid-phase permethylation for glycomic analysis. , 2009, Methods in molecular biology.

[19]  L. R. Ruhaak,et al.  Developments in the Identification of Glycan Biomarkers for the Detection of Cancer , 2013, Molecular & Cellular Proteomics.

[20]  Yehia Mechref,et al.  Solid-phase permethylation of glycans for mass spectrometric analysis. , 2005, Rapid communications in mass spectrometry : RCM.

[21]  Scott R. Kronewitter,et al.  Glycomics and disease markers. , 2009, Current opinion in chemical biology.

[22]  Y. Mechref,et al.  Identification of N-glycan serum markers associated with hepatocellular carcinoma from mass spectrometry data. , 2010, Journal of proteome research.

[23]  Adrian M Di Bisceglie,et al.  Diagnosis of hepatocellular carcinoma. , 2005, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[24]  Hyun Joo An,et al.  Determination of glycosylation sites and site-specific heterogeneity in glycoproteins. , 2009, Current opinion in chemical biology.

[25]  Xiaobo Song,et al.  Modification of Sialylation Mediates the Invasive Properties and Chemosensitivity of Human Hepatocellular Carcinoma* , 2013, Molecular & Cellular Proteomics.

[26]  Kiyoko F. Aoki-Kinoshita,et al.  KEGG as a glycome informatics resource. , 2006, Glycobiology.

[27]  Y. Mechref,et al.  Comparative glycomic profiling of isotopically permethylated N-glycans by liquid chromatography/electrospray ionization mass spectrometry. , 2013, Rapid communications in mass spectrometry : RCM.

[28]  H. Usuki,et al.  Outer arm fucosylation of N-glycans increases in sera of hepatocellular carcinoma patients. , 2008, Biochemical and biophysical research communications.

[29]  Samir Gupta,et al.  Test Characteristics of -Fetoprotein for Detecting Hepatocellular Carcinoma in Patients with Hepatitis C , 2003, Annals of Internal Medicine.

[30]  Y. Mechref,et al.  Detection of Hepatocellular Carcinoma Using Glycomic Analysis , 2009, Clinical Cancer Research.

[31]  Ruedi Aebersold,et al.  High-throughput generation of selected reaction-monitoring assays for proteins and proteomes , 2010, Nature Methods.

[32]  J. Gu,et al.  Branched N‐glycans regulate the biological functions of integrins and cadherins , 2008, The FEBS journal.

[33]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Y. Mechref,et al.  Enhanced sensitivity of LC‐MS analysis of permethylated N‐glycans through online purification , 2011, Electrophoresis.

[35]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[36]  H. M. Reis,et al.  Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma , 2013, Nature Reviews Cancer.

[37]  Yehia Mechref,et al.  Comparing MALDI‐MS, RP‐LC‐MALDI‐MS and RP‐LC‐ESI‐MS glycomic profiles of permethylated N‐glycans derived from model glycoproteins and human blood serum , 2012, Electrophoresis.

[38]  Zhao-You Tang,et al.  Elevated activity of N -acetylglucosaminyltransferase V in human hepatocellular carcinoma , 1998, Journal of Cancer Research and Clinical Oncology.

[39]  Joris R Delanghe,et al.  Diagnostic value of the hemopexin N-glycan profile in hepatocellular carcinoma patients. , 2010, Clinical chemistry.

[40]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[41]  Ullrich Köthe,et al.  SIMA: Simultaneous Multiple Alignment of LC/MS Peak Lists , 2011, Bioinform..